Iron and reactive oxygen species activity in parkinsonian substantia nigra

Parkinsonism and Related Disorders

Volumn 16, Issue 5, 2010, Pages 329-333

  Wypijewska, Anna ^a   Galazka Friedman, Jolanta ^b   Bauminger, Erika R ^c   Wszolek, Zbigniew K ^d   Schweitzer, Katherine J ^d   Dickson, Dennis W ^d   Jaklewicz, Andrzej ^e   Elbaum, Danek ^f   Friedman, Andrzej ^e  

^a UNIVERSITY OF WARSAW   (Poland)

^b WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d MAYO CLINIC   (United States)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f INSTITUTE OF PHYSICS   (Poland)

Author keywords

Labile iron; Oxidative stress; Parkinson disease; Reactive oxygen species

Indexed keywords

COPPER; IRON; IRON BINDING PROTEIN; REACTIVE OXYGEN METABOLITE;

AGED; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN TISSUE; LIGHT; MOSSBAUER SPECTROSCOPY; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TISSUE LEVEL;

COPPER; FEMALE; HUMANS; IRON; IRON-BINDING PROTEINS; MALE; PARKINSONIAN DISORDERS; REACTIVE OXYGEN SPECIES; SPECTROPHOTOMETRY, ATOMIC; SUBSTANTIA NIGRA;

EID: 77952951413     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.02.007     Document Type: Article

References (30)

1. Halliwell B. Oxygen radicals as key mediators in neurological disease: fact or fiction?. Ann Neurol 1992, 32(Suppl):S10-S15.
2. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neurol Transm 1988, 74:199-205.
3. Griffiths P.D., Crossman A.R. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 1993, 4:61-65.
4. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994, 36:876-881.
5. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114:1953-1975.
6. Youdim M.B., Ben-Shachar D., Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?. Acta Neurol Scand Suppl 1989, 126:47-54.
7. Uitti R.J., Rajput A.H., Rozdilsky B., Bickis M., Wollin T., Yuen W.K. Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. Can J Neurol Sci 1989, 16:310-314.
8. Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 1995, 65:710-724.
9. Galazka-Friedman J., Bauminger E.R., Friedman A., Barcikowska M., Hechel D., Nowik I. Iron in parkinsonian and control substantia nigra: a Mossbauer spectroscopy study. Mov Disord 1996, 11:8-16.
10. Friedman A., Galazka-Friedman J., Bauminger E.R. Iron as a trigger of neurodegeneration in Parkinson's disease. Handb Clin Neurol 2007, 83:493-505.
11. Gerlach M., Trautwein A.X., Zecca L., Youdim M.B.H., Riederer P. Mossbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J Neurochem 1995, 65:923-926.
12. Dubiel S.M., Zablotna-Rypien B., Mackey J.B. Magnetic properties of human liver and brain ferritin. Eur Biophys J 1999, 28:263-267.
13. Harrison P.M., Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996, 1275:161-203.
14. Koziorowski D., Friedman A., Arosio P., Dziewulska D. ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control. Parkinsonism Relat Disord 2007, 13:214-218.
15. Gerlach M., Riederer P., Double K.L. Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2008, 14:S185-S188.
16. Zecca L., Gallorini M., Schunemann V., Trautwein A.X., Gerlach M., Riederer P., et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 2001, 76:1766-1773.
17. Galazka-Friedman J., Bauminger E.R., Friedman A., Koziorowski D. Szlachta K- Human nigral and liver iron - comparison by Mössbauer spectroscopy, electron microscopy and ELISA. Hyperfine Interact 2005, 165:285-288.
18. Fasano M., Bergamasco B., Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem 2006, 96:909-916.
19. Bolzoni F., Giraudo S., Lopiano L., Bergamasco B., Fasano M., Crippa P.R. Magnetic investigations of human mesencephalic neuromelanin. Biochim Biophys Acta 2002, 1586:210-218.
20. Zecca L., Stroppolo A., Gatti A., Tampellini D., Toscani M., Gallorini M., et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A 2004, 101:9843-9848.
21. Litvan I., Bhatia K.P., Burn D.J., Goetz C.G., Lang A.E., McKeith I., et al. Movement disorders society scientific issues committee movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003, 18:467-486.
22. Bauminger E.R., Harrison P.M., Nowik I., Treffry A. Mossbauer spectroscopic study of the initial stages of iron-core formation in horse spleen apoferritin: evidence for both isolated Fe(III) atoms and oxo-bridged Fe(III) dimers as early intermediates. Biochemistry 1989, 28:5486-5493.
23. Ma Y., de Groot H., Liu Z., Hider R.C., Petrat F. Chelation and determination of labile iron in primary hepatocytes by pyridinone fluorescent probes. Biochem J 2006, 395:49-55.
24. Brzyska M., Bacia A., Elbaum D. Oxidative and hydrolytic properties of beta-amyloid. Eur J Biochem 2001, 268:3443-3454.
25. Snyder A.M., Connor J.R. Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 2009, 1790:606-614.
26. Tapiero H., Townsend D.M., Tew K.D. Trace elements in human physiology and pathology: copper. Biomed Pharmacother 2003, 57:386-398.
27. Calabrese V., Lodi R., Tonon C., D'Agata V., Sapienza M., Scapagnini G., et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci 2005, 233:145-162.
28. Barnham K.J., Bush A.I. Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol 2008, 12:222-228.
29. Zecca L., Zucca F.A., Albertini A., Rizzio E., Fariello R.G. A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology 2006, 67(7 Suppl. 2):S8-S11.
30. Gassen M., Youdim M.B.H. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol Toxicol 1997, 80:159-166.